PEGylated Hyaluronic Acid Nanoparticle Drug Delivery

A research group from the Republic of Korea developed poly(ethylene glycol)-conjugated hyaluronic acid nanoparticles (PEG-HANPs) with high tumor targetability. Doxorubicin (DOX) was chosen as the model anticancer drug and was effectively encapsulated into the mineralized nanoparticles. “The most effective antitumor efficacy was observed for DOX-loaded PEG-HANPs. Overall, these results suggest that PEG-HANPs could be a promising carrier for an anticancer drug.” A major drawback of hyaluronic acid (HA)-based drug nanoparticles for cancer therapy is their preferential accumulation in the liver after systemic administration. It is believed that PEGylation could effectively increase their circulation time in the blood and alter their tissue distribution. This work is published in the Journal of Controlled Release. “Robust PEGylated hyaluronic acid nanoparticles as the carrier of doxorubicin: Mineralization and its effect on tumor targetability in vivo”. Journal of Controlled Release, 2013, 168(2):105–114. DOI: 10.1016/j.jconrel.2013.02.022.

Full-size image (25 K)Image: courtesy of the publisher and authors

PEGylated hyaluronic acid products: Creative PEGWorks provides a special collection of hyaluronic acid (M.W. 10, 50, 500, 750, 1000, 1500, and 2500 kDa) functionalized or grafted with polyethylene glycol polymers (M.W. 2, 5 and 10 kDa). Degree of substitution from 1 to 10 MOL % can be offered.

This entry was posted in PEG Derivatives, PEGylation Reagents, PEGylation Success Stories and tagged , , , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s